Vanderbilt Vaccine Research Program

Vanderbilt joins national effort to develop alphavirus vaccines

The project aims to design computational “tool kits” that can speed development of multi-virus vaccines targeting some of the greatest infectious threats to human health.

Antibody trial launched to address enterovirus threat

Enterovirus D68 has caused an increasing number of infections during the past decade and is associated with acute flaccid myelitis, a polio-like condition that mostly affects children and causes sudden weakness and paralysis.

Bird flu vaccine more effective with potent adjuvant

The avian (bird) influenza vaccine creates a more robust immune response when paired with a potent ingredient known as an adjuvant, according to Vanderbilt research published in The Journal of Infectious Diseases.

Study finds Moderna’s COVID-19 vaccine safe and effective for young children

A Vanderbilt study finds that Moderna’s COVID-19 vaccine is safe and effective in children 6 months to 5 years of age.

VUMC study will evaluate alternative strategies for administering mpox vaccine

Rarely fatal, the mpox virus — spread by close, often skin-to-skin contact — causes a painful, blistering rash, fever, chills and other symptoms.

Study to evaluate nasal flu vaccine for children

Pediatricians with the Vanderbilt Vaccine Research Program are looking for healthy infants and children (6 months – 8 years of age) to take part in a nasal influenza vaccine study.

1 2 3